We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions surrounding Crystal Amber Fund Limited (CRS) highlighted a notable shift in sentiment following recent developments in the broader investment trust sector. One significant incident referenced was the failure of the US activist investor Saba Capital to secure changes in the boards of Henderson Opportunities and CQS Natural Resources Growth & Income. This event seems to have caused a ripple effect among shareholders, raising concerns about the effectiveness of activist strategies in influencing board composition within investment trusts.
Financial highlights from the discussions were generally cautious, with investors expressing anxieties about governance and active management in the current economic environment. The sentiment appears tempered, as many participants reflected on the recent voting outcomes as potential indicators of growing shareholder resistance to activist interventions. Comments such as "Investors seem to be tightening their grip on board interventions" encapsulated the cautious tone prevalent in the discussions, as stakeholders weigh the implications for their investments in CRS amidst an increasingly skeptical market. Overall, while there remains an interest in the fund's performance, the recent developments have led to a more measured approach among investors.
Show more
Crystal Amber Fund Limited has reported significant updates regarding its voting rights and share transactions for the period ending March 2, 2025. As of February 28, 2025, the company has 99,749,762 ordinary shares in issue, with 68,050,000 being voting rights, following an announcement of total voting rights in compliance with the Disclosure Guidance and Transparency Rules. Additionally, the company holds 31,699,762 ordinary shares in Treasury, and this voting rights figure will assist shareholders in determining their notification obligations under corporate regulations.
On February 24, 2025, Crystal Amber Fund revealed a buyback of 150,000 of its ordinary shares at £1.23 each, which will be cancelled, as authorized by shareholders during the Annual General Meeting held on December 13, 2024. This transaction underscored the company's commitment to managing its share capital effectively. Furthermore, the Merseyside Pension Fund crossed a threshold in its voting rights held in the company, signaling potential shifts in shareholder dynamics that might influence future strategic decisions. These developments reflect a proactive stance by Crystal Amber Fund in enhancing shareholder value and maintaining regulatory transparency.
Show more
I'm pleasantly surprised that they are doubling down on their estimate of NAV. DLAR has been strong but there is only Morphic to make up the difference between the claimed NAV and the market share price Allied Minds could surprise I suppose but not more than 5 to 10 pence with a very fair wind. DLAR getting an offer would be very helpful. |
See from oost 822 that it is.... Wow |
Is it till the end of January purchases to be made by? |
I think you are reading it right..these could easily be walked up if Winterflood push the pedal, if no meaningful seller emerges then should move higher..imagine it is in Wins interest to get it done. |
So to be clear. |
Gem |
The stock market has been on a tear over the last month on hopes for a dovish pivot from the Fed, but investors like me have seen this movie before whereby i'm left pondering if to sell off 30% of my $450k portfolio which comprised of plummeting stocks or hold on. |
Referencing Morphic Medical , the developed world needs a multi pronged approach both medicinal and physical to deal with growing health issues associated with obesity.Cost to UK alone is a massive issue and it would appear highly cost effective to employ non surgical intervention.https:/ |
Good move, buying back nearly 10 percent of company 👍 |
Looks to me like the co. putting a concrete floor under the share price.. should create a sort of ratcheting-up of the price. |
If CA cannot get an exit on at least one of the four hopeful prospects at ALM, they risk being diluted by cash calls to the point where the cost of keeping the ALM holding becomes more than it's worth. That is the problem, and one Sam Dobbyn was sent in to avoid. It is a bit too early to throw in the towel but there needs to be some concrete news next year. (I'll give Dobbyn 2024. Meanwhile a response to his bosses might be wise ...) |
If only ALM had managed to monetise investments and return funds to shareholder as CRS have...unfortunately it seems to go from bad to worse there...luckily now a very small investment to CRS. |
Saba still have a big interest in a company that (supposedly) trades at a >30% discount to its NAV. |
Clear that Saba again tried to throw their weight around to get something and exert control...again it seems that they do not have the controlling interest they would like. The company has done well in returning value to holders since Saba surfaced and wanted it wound up , if it had been done as a fire sale other shareholders would have suffered value destruction. So pleased to see that Saba are unable to force their will on the running of the company by voting down directors..likely will get back in their cage again realising this. |
Result of the AGM RNS issued at 10:50 AM. Worth quoting: |
I guess one issue is, anything UK listed is likely to be on a low rating... |
UBG ... interesting shout. Not sure what caused them to miss their deadline, nor what Transaction they have been hoping for. |
Mine is CNSL |
Such as UBG? |
Finally some share price interest ahead of AGM which may update on Morphic. I would like to see Morphic acquire a zombie company for a listing (I have one in mind that would suit, but there must be many after Covid chaos in Downing Street). Then they could wind down quickly. We'll see on Wednesday. |
A dwindling pot of assets and high management fees .... PIs won't have much say ... don't get caught out :-( |
Following further investment of GBP8.3 million in Morphic Medical since the beginning of 2022 and combined with cash returns of 55p a share, Morphic Medical now accounts for 40 per cent of net asset value. |
The nhs is widening its non invasive treatments this news from a few weeks ago is a similar type procedure that is just being adopted , im unsure of the pros and cons of the different approaches but there appears increased demand for non medicinal approach to obesity.https://news |
Type | Ordinary Share |
Share ISIN | GG00B1Z2SL48 |
Sector | Unit Inv Tr, Closed-end Mgmt |
Bid Price | 122.00 |
Offer Price | 128.00 |
Open | 124.00 |
Shares Traded | 42,073 |
Last Trade | 08:06:52 |
Low - High | 123.00 - 125.00 |
Turnover | 58.84M |
Profit | 57.29M |
EPS - Basic | 0.7587 |
PE Ratio | 1.65 |
Market Cap | 94.01M |
Trade activities that have, in the recent past, portended a dominance as regards buying and selling in the exchanges of Gulf Keystone Petroleum Ltd. (LSE:GKP) have been that bulls are tending to head out bears in the subsequent movements, given that the price currently holds positively, waxing higher below 200 values. In the interim, the ...
Continue Reading
Formerly, in the proceedings of striving to hold back against a fearful drawn-down, the market fluctuated in a series of ranges around 35 between December and some days back into this month of February, as the ITM Power Plc (LSE:ITM) stock operation eventually further broke downward against 30, searching for a baseline toward the support ...
Continue Reading
During a recent episode of The Liberty Report, Ron Paul and his co-host Daniel McAdams examined the increasing skepticism toward the Federal Reserve, a sentiment amplified by public frustration over government spending and financial fraud, particularly in light of Elon Musk’s Department of Government Efficiency (DOGE) revealing inst...
Continue Reading
London stocks fell in early trade on Friday, taking their cue from heavy losses in the US and Asia amid concerns about Donald Trump’s tariff threats. At 0828 GMT, the FTSE 100 was down 0.4% at 8,723.95. Derren Nathan, head of equity research at Hargreaves Lansdown, said: “Tariffs continue to drive the narrative, and talk ...
Continue Reading
President Donald Trump has decided that “We are not going to do the wind thing”. Specifically, he has put a stop to the leasing of new wind power facilities in the Offshore Continental Shelf (OCS), and suspended leases for both onshore and offshore wind projects in the USA. He will also attempt to find legal […]
Continue Reading
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions